Influenza alert in three years

↓99.9% regenerative medicine market

5.1 per 1,000 patients first week of September, breaking five in six months two years

The flu treatment market has shrunk by 99.9% in three years, and expectations for a rebound in the prescription market are high

The influenza (flu) alert, which disappeared after the spread of COVID-19, was issued.

 

September 12 years after 2010, influenza alert has come.

 

The pharmaceutical industry is Corona 19 that virtually died out after the spread of flu drug market to expect a revival of the atmosphere.

 

According to the industry on the 19th, the Korea Centers for Disease Control and Prevention issued a flu epidemic warning nationwide on the 16th.

 

The Korea Centers for Disease Control and Prevention issued a flu pandemic warning nationwide between September 4 and September 10 this year, with 5.1 suspected flu patients per 1,000 outpatients exceeding the epidemic standard (4.9).

 

The number of suspected cases per 1,000 for the past 23 weeks, outpatient clinics, flu, the highest this year.

 

4.8 members leapt over the last 12 weeks.

 

In previous years, the flu epidemic standard was set at 5.8 per 1,000 outpatients, but this year, COVID-19 and the flu are likely to spread at the same time.

 

It is the first time in two years and six months that the number of suspected flu patients per 1,000 outpatients has exceeded five since the ninth week of 2020.

 

It has never exceeded five since it recorded 6.3 in the ninth week of the first week of March 2020.

 

This means that the flu has never been prevalent for more than two years.

 

This is the aftermath of a significant decrease in the incidence of infectious diseases due to strengthening personal hygiene management such as hand washing and wearing masks after the spread of COVID-19.

 

As social distancing was lifted this year, the number of flu patients gradually increased.

 

In the last 24 weeks, the number of suspected flu patients per 1,000 outpatients was only 1.8 but tripled in three months.

 

The pharmaceutical industry is expecting a rebound in flu treatments that have virtually disappeared since the spread of COVID-19.

 

According to UBIST, a drug research institute, the amount of outpatient prescriptions for flu treatments in 2019 recorded 22.5 billion won.

 

However, it fell to 8.8 billion won in 2020, and only reached 40 million won last year.

 

In the past two years, the size of the flu treatment market has decreased by 99.8%.

 

It was reduced by 99.9% in three years from 44.7 billion won in 2018.

 

The flu treatment market recorded 8.4 billion won in the first quarter of 2020, but plunged 99.8% to around 10 million won in the second quarter when COVID-19 began to spread in earnest.

 

The flu treatment market recorded less than 100 million won for nine consecutive quarters from the second quarter of 2020.

 

In the first half of this year, the prescription for flu treatment was less than 100 million won.

 

After the spread of COVID-19, the flu treatment market virtually disappeared as the number of flu patients decreased sharply due to strengthening personal hygiene management such as washing hands and wearing masks.

 

The Oseltamivir market, which is most commonly used as a flu treatment, has virtually disappeared.

 

Oseltamivir is the active ingredient of Tamiflu.

 

In the first half of this year, Oseltamivir's out patient prescription market was only 92 million won.

 

It was only 60 million won in the first quarter and 32 million won in the second quarter.

 

The size of Oseltamivir prescription in 2019 recorded 22.4 billion won, falling to 8.7 billion won in 2020 and shrinking to 40 million won last year.

 

Pharmaceutical companies expect the flu treatment market to rebound as the number of flu patients increases.

 

An industry official said, "We will consider whether to expand the production and supply of treatments while looking at the trend of expanding flu patients in the future."